Compare Stocks: SGEN, VRTX, REGN, and MRNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$184.37 +1.0%	$104.13	$22.28 ▼ $192.31	$73.28B	1.1	11.78 million shs	10.95 million shs
REGN Regeneron Pharmaceuticals	$794.70 -1.1%	$772.49	$541.00 ▼ $859.34	$81.89B	0.2	828,195 shs	161,960 shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	N/A
VRTX Vertex Pharmaceuticals	$511.33 -0.7%	$513.19	$374.17 ▼ $560.25	$129.79B	0.32	1.39 million shs	244,568 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	+5.56%	+26.98%	+25.84%	+202.15%	+587.35%
REGN Regeneron Pharmaceuticals	+0.72%	+3.85%	-3.61%	+28.85%	+34.96%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%
VRTX Vertex Pharmaceuticals	+0.84%	+0.07%	-6.03%	+8.37%	+34.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$184.37 +1.0%	$104.13	$22.28 ▼ $192.31	$73.28B	1.1	11.78 million shs	10.95 million shs
REGN Regeneron Pharmaceuticals	$794.70 -1.1%	$772.49	$541.00 ▼ $859.34	$81.89B	0.2	828,195 shs	161,960 shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	N/A
VRTX Vertex Pharmaceuticals	$511.33 -0.7%	$513.19	$374.17 ▼ $560.25	$129.79B	0.32	1.39 million shs	244,568 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	+5.56%	+26.98%	+25.84%	+202.15%	+587.35%
REGN Regeneron Pharmaceuticals	+0.72%	+3.85%	-3.61%	+28.85%	+34.96%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%
VRTX Vertex Pharmaceuticals	+0.84%	+0.07%	-6.03%	+8.37%	+34.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNA Moderna	2.13	Hold	$76.72	-58.39% Downside
REGN Regeneron Pharmaceuticals	2.58	Moderate Buy	$802.18	0.94% Upside
SGEN Seagen	0.00	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	2.96	Moderate Buy	$573.83	12.22% Upside

Current Analyst Ratings Breakdown

Latest SGEN, VRTX, REGN, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/21/2026	REGN Regeneron Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/21/2026	VRTX Vertex Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$594.00
9/11/2026	VRTX Vertex Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$515.00 ➝ $560.00
9/10/2026	VRTX Vertex Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/10/2026	REGN Regeneron Pharmaceuticals	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$800.00 ➝ $920.00
9/9/2026	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
9/3/2026	MRNA Moderna	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$40.00 ➝ $81.00
9/1/2026	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$665.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNA Moderna	$1.94B	37.86	N/A	N/A	$22.14 per share	8.33
REGN Regeneron Pharmaceuticals	$14.34B	5.70	$41.80 per share	19.01	$295.66 per share	2.69
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15
VRTX Vertex Pharmaceuticals	$12.00B	10.81	$17.60 per share	29.06	$73.57 per share	6.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.66	15.73	1.56	27.86%	13.47%	10.34%	10/28/2026 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A
VRTX Vertex Pharmaceuticals	$3.95B	$17.18	29.77	27.97	2.24	35.00%	23.09%	16.72%	11/2/2026 (Estimated)

Latest SGEN, VRTX, REGN, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026	VRTX Vertex Pharmaceuticals	$4.74	$4.73	-$0.01	$4.31	$3.23 billion	$3.33 billion
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.47%	N/A	9.29%	N/A
SGEN Seagen	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest SGEN, VRTX, REGN, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNA Moderna	0.09	2.29	2.18
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
SGEN Seagen	N/A	2.67	2.12
VRTX Vertex Pharmaceuticals	N/A	3.19	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRNA Moderna	75.33%
REGN Regeneron Pharmaceuticals	83.31%
SGEN Seagen	84.26%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
MRNA Moderna	10.80%
REGN Regeneron Pharmaceuticals	6.97%
SGEN Seagen	25.90%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	No Data
VRTX Vertex Pharmaceuticals	6,400	253.80 million	253.30 million	Optionable

SGEN, VRTX, REGN, and MRNA Headlines

Recent News About These Companies

Leerink Partners Begins Coverage on Vertex Pharmaceuticals (NASDAQ:VRTX)

September 23 at 1:30 AM | americanbankingnews.com

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

September 22 at 2:46 PM | msn.com

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder

September 22 at 2:46 PM | stocktwits.comS

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

September 22 at 2:10 PM | benzinga.com

State Street Corp Has $5.90 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX

September 22 at 1:04 PM | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

September 22 at 10:01 AM | zacks.com

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of ...

September 22 at 9:44 AM | markets.ft.com

Vertex reports kidney drug trial results

September 22 at 9:44 AM | grafa.comG

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

September 22 at 9:44 AM | finance.yahoo.com

Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026

September 22 at 9:44 AM | finance.yahoo.com

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

September 22 at 9:44 AM | finance.yahoo.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated at Leerink Partners

September 21 at 10:05 AM | marketbeat.com

Vertex Pharma stock slips 1.55 percent pre-market before the open

September 20 at 12:01 AM | ad-hoc-news.deA

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

September 18, 2026 | zacks.com

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

September 18, 2026 | fool.com

2 Reasons to Like VRTX (and 1 Not So Much)

September 18, 2026 | finance.yahoo.com

Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan

September 18, 2026 | finance.yahoo.com

Nykredit A S Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

September 18, 2026 | marketbeat.com

Baird Financial Group Inc. Has $2.05 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

September 18, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Consensus Rating of "Moderate Buy" by Brokerages

September 18, 2026 | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Brokerages

September 18, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SGEN, VRTX, REGN, and MRNA Company Descriptions

Moderna NASDAQ:MRNA

$184.37 +1.81 (+0.99%)

As of 11:44 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$794.70 -9.20 (-1.14%)

As of 11:44 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Vertex Pharmaceuticals NASDAQ:VRTX

$511.33 -3.66 (-0.71%)

As of 11:44 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGEN, VRTX, REGN, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGEN, VRTX, REGN, and MRNA Earnings

Compare Dividends

Latest SGEN, VRTX, REGN, and MRNA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGEN, VRTX, REGN, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SGEN, VRTX, REGN, and MRNA Company Descriptions

Moderna NASDAQ:MRNA

Regeneron Pharmaceuticals NASDAQ:REGN

Seagen NASDAQ:SGEN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools